Received Dec 17, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | X5SN4 | — |
patient got double dose of the diluent portion of SHINGRIX instead of the reconstituted dose; patient got double dose of the diluent portion of SHINGRIX instead of the reconstituted dose; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of inappropriate dose of vaccine administered in a 74-year-old female patient who received Herpes zoster (Shingrix) (batch number X5SN4, expiry date 17-JUN-2027) for prophylaxis. On 11-DEC-2025, the patient received Shingrix. On 11-DEC-2025, an unknown time after receiving Shingrix, the patient experienced inappropriate dose of vaccine administered (Verbatim: patient got double dose of the diluent portion of SHINGRIX instead of the reconstituted dose) and inappropriate preparation of medication (Verbatim: patient got double dose of the diluent portion of SHINGRIX instead of the reconstituted dose). The outcome of the inappropriate dose of vaccine administered and inappropriate preparation of medication were not applicable. Additional Information: GSK receipt date: 11-DEC-2025 On 11 December 2025, a pharmacist had called to seek guidance after a patient had received a double dose of the diluent portion of Shingrix instead of the reconstituted vaccine dose. The pharmacist had asked whether a complete dose could still be administered to complete the vaccine series, noting that three adjuvants had been given.